Unveiling Patient Experiences in Testicular Cancer Clinical Trials

NCT05928377 | Not Yet Recruiting

• 1 other identifier: 80505443
• Study Type: observational
• Target: 500
• Locations: 1 country
• Sites: 1

Brief Summary

Clinical research participation has historically been heavily biased toward specific demographics. Several people will be invited to enroll in this study so that it may collect a variety of data about testicular cancer clinical study experiences and identify barriers to participation as well as the causes of participants' failure or withdrawal. People with testicular cancer who are invited to take part in medical research will benefit from the analysis of the data.

Conditions

Testicular Cancer

Keywords

testicular cancer

Outcome Measures

Primary Outcomes (2)

• Number of testicular cancer patients who decide to enroll in a clinical trial

  3 months

• Rate of testicular cancer patients who remain in a clinical trial to trial completion

  12 months

Eligibility Criteria

• Age: 18 Years+
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Testicular cancer patients who are actively considering enrolling in a clinical trial for the said condition, but have not yet completed enrollment and randomization phases.

You may qualify if:

• Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
• Diagnosis of testicular cancer
• No prior treatment for testicular cancer

You may not qualify if:

• Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
• Enrolled in another research study
• Inability to provide written informed consent

Sponsors & Collaborators

• Power Life Sciences Inc.: lead

Study Sites (1)

Power Life Sciences

San Francisco, California, 94107, United States

Location

Related Publications (3)

• Ljungman L, Eriksson LE, Flynn KE, Gorman JR, Stahl O, Weinfurt K, Wiklander M, Lampic C, Wettergren L. Sexual Dysfunction and Reproductive Concerns in Young Men Diagnosed With Testicular Cancer: An Observational Study. J Sex Med. 2019 Jul;16(7):1049-1059. doi: 10.1016/j.jsxm.2019.05.005.

  PMID: 31255211 BACKGROUND

• Selvi I, Sarikaya S, Basar H. Is testicular microlithiasis a really innocent condition? Its effects on oncological outcomes of germ cell testicular cancer: An observational study. Arch Esp Urol. 2020 Apr;73(3):215-229. English, Spanish.

  PMID: 32240112 BACKGROUND

• Pedersen MR, Sloth Osther PJ, Nissen HD, Vedsted P, Moller H, Rafaelsen SR. Elastography and diffusion-weighted MRI in patients with testicular microlithiasis, normal testicular tissue, and testicular cancer: an observational study. Acta Radiol. 2019 Apr;60(4):535-541. doi: 10.1177/0284185118786063. Epub 2018 Jul 3.

  PMID: 29969051 BACKGROUND

MeSH Terms

Conditions

Testicular Neoplasms

Condition Hierarchy (Ancestors)

Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Male Urogenital Diseases; Endocrine System Diseases; Testicular Diseases; Gonadal Disorders

Study Officials

• Michael B Gill

  Power Life Sciences Inc.

  STUDY DIRECTOR

Central Study Contacts

Michael B Gill

CONTACT

4159004227; bask@withpower.com

Study Design

• Study Type: observational
• Observational Model: CASE CROSSOVER
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 23, 2023
• First Posted: July 3, 2023
• Study Start: July 1, 2024
• Primary Completion: July 1, 2025
• Study Completion (Estimated): July 1, 2026
• Last Updated: July 3, 2023

Record last verified: 2023-06

Locations

US (1)